Summary Photodynamic therapy consists of the systemic administration of a derivative of haematoporphyrin (Photofrin 11) followed 24-72 h later by exposure of malignant lesions to photoradiation. We investigated the efficacy of this treatment after direct intratumoral injection of Photofrin II. This direct treatment regimen resulted in higher rates of inhibition of mitochondrial cytochrome c oxidase (5.13% J' cmM2 x 10-') and succinate dehydrogenase (3.14% J-' cm-2 X 10-I) in vitro at 2 h after intratumoral injection compared to rates of inhibition obtained after intraperitoneal drug administration: 0.51 and 0.42% J -I cm-2 x 10-', respectively. A significant delay in tumour growth in vivo was observed in animals that received intratumoral injections 2 h before photoradiation compared to animals injected intraperitoneally at either 2 or 24 h before photoradiation. The treatment protocols were compared with control groups, consisting of Photofrin II administration intratumorally or intraperitoneally without photoradiation, or photoradiation in the absence of Photofrin II. These data indicate that the intratumoral injection regimen with Photofrin II enhanced the efficacy of photodynamic therapy. The greater delay in tumour growth observed after intratumoral administration of Photofrin II suggests a mechanism favouring direct cell damage.
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Photodynamic therapy (PDT), a promising therapeutic modality for the management of various types of malignancies, employs a combination of the systemic administration of a photosensitiser (Photofrin II) with the direct exposure of tumours to visible irradiation, a protocol that results in metabolic inhibition of malignant cells in vitro and in vivo (Hilf et al., , 1987 Kessel, 1986; Ceckler et al., 1986) . The photosensitised damage is attributed to production of the highly reactive oxygen species, singlet oxygen, which is formed upon exposure of the porphyrin components in Photofrin II to visible light (Weishaupt et al., 1976; Gibson et al., 1984a; Parker, 1987) . Two features of PDT are noteworthy. The hydrophobic components (Dougherty, 1987; Kessel et al., 1987) of Photofrin II (presumably di-haematoporphyrin ethers and/or esters) are retained for longer periods in tumour tissue than in most normal tissues (Gomer & Dougherty, 1979; Kostron et al., 1986; Steichen et al., 1986; Lin et al., 1988a) , resulting in a favourable tumour to normal tissue ratio of photosensitiser. By creating a therapeutic window at selected times after drug administration, irradiation would produce minimal deleterious effects in the surrounding normal tissues due to their reduced porphyrin content. The second feature of PDT is the ability to deliver focused visible light energy via laser fibre optics, thus providing a precise tumour treatment. The typical clinical PDT protocol consists of the systemic administration of 2-5 mg kg-' Photofrin 11 followed 24-72 h later by exposure of malignant lesions to 50-400 J cm-2 visible photoradiation, usually 630 nm laser emission. Utilising these treatment conditions for various types of malignancies, encouraging clinical results have been reported (Kato et al., 1986; Lam et al., 1987; Gilson et al., 1988; Nseyo et al., 1987; McCaughan et al., 1988) . Any improvement in the efficacy of PDT should increase its acceptance as a useful cancer treatment.
Some additional information has been reported recently to improve PDT by modifying the standard treatment protocol. Lin et al. (1988b) compared effects of PDT after injecting Photofrin II directly into the tumour versus intraperitoneal injection. Although they found no significant difference in the response of a murine bladder tumour, assessed by measuring cell survival in vitro, they suggested that the effects observed may occur by different mechanisms, i.e. induction of vascular damage after i.p. administration versus direct cytotoxicity after intratumoral injection (Lin et al., 1988b Animals and tumours The R3230AC mammary adenocarcinoma was maintained by transplantation into the axillary region of 80-100 g female Fischer rats, using the sterile trochar method described earlier (Hilf et al., 1965 range is estimated to be less than 10% of tumour volume and is usually focal in nature; it was not thought to alter significantly either the distribution or clearance of the injected Photofrin II. The animals were killed at selected times, tumours and livers were surgically excised in dimmed room light, and suspensions of mitochondria were prepared from whole tissues and stored in I ml aliquots at -70°C until assayed (Gibson & Hilf, 1983) .
Photoradiation of mitochondrial suspensions in vitro One ml aliquots of tumour or liver mitochondrial suspensions were removed from storage, thawed at room temperature and adjusted to the desired initial enzyme activity by dilution with preparation buffer (see below) before photoradiation of the suspensions in vitro. One ml aliquots of these suspensions were exposed to photoradiation emitted from a filtered (570-700 nm) focused quartz halogen light source. The samples placed in 3 ml quartz cuvettes were positioned in the 1 cm diameter focussed beam and irradiated with a power density of 150 mW cm-2, measured by a power radiometer (Model Rk 5200, Laser Precision, Utica, NY, USA) connected to an Rk 545 radiometer probe. The suspensions were stirred magnetically and, at selected times, samples (10-40 jd) were removed for analysis of enzyme activity. Temperature of the suspensions, which was monitored during the irradiation period (1 h, 540 J cm-2 total fluence), did not rise above ambient (25°C).
Enzyme activity analysis The activities of cytochrome c oxidase and succinate dehydrogenase were analysed at various intervals during the in vitro exposure of the mitochondrial suspensions to photoradiation. Before photoradiation, liver or tumour suspensions were adjusted to selected initial enzyme activities by dilution with the preparation buffer (0.33 M sucrose, 1 mM dithiothreitol, 1 mM EGTA, 0.03% bovine serum albumin and 100 mM KCI); these activities were 0.4-0.61mol cytochrome c oxidised per min per mg protein for cytochrome c oxidase and 4.6-8.3 x 10-2mmol p-iodonitrotetrazolium violet (INT) oxidised per min per mg protein for succinate dehydrogenase.
Laser photoradiation of tumours in vivo Tumours, borne on host animals administered Photofrin II, were photoradiated after reaching a size of 0.4-0.9 cm2 surface area (calculated from two opposing diagonal caliper measurements), which corresponded to a volume range of 0.18-0.54 cm3 (see below) and a final drug dose of 0.81-1.55 mg kg-' body weight (b.w.). Animals were apportioned to each treatment group to provide similar tumour size ranges. The tumour volumes employed in this aspect, involving tumour growth behaviour in vivo, were smaller than those used above in the in vivo-in vitro protocol. Smaller tumours could be used since it was not necessary to obtain large amounts of tissue for subsequent preparation of subcellular organelles. Further, as tumour size increases, PDT is less effective, presumably due to insufficient light penetration resulting in cytotoxicity only in the outermost regions of the lesion. The tumours were exposed to a 1 cm diameter beam emitted from a fibre optic cable fitted with a cylindrical lens and coupled to an argon pumped tunable dye laser (Coherent, Palo Alto, CA, USA). Power density incident on the tumours was adjusted to 200 mW cm-2 as measured using a power radiometer (RK5200, Laser Precision, Utica, NY, USA). (Gibson et al., 1989 ). Here we examined whether such a dose relationship existed after Photofrin II was administered intratumorally (i.t.). Two hours before killing, Photofrin II was administered i.t. at doses equivalent to 0.25, 0.5, 2.5 or 5.0 mg kg', and mitochondria prepared from tumour and liver were exposed to photoradiation (see Materials and methods). The data for cytochrome c oxidase (Figure 1 ) are presented to demonstrate that both a drug-dose and lightdose relationship existed for the inhibition of this enzyme and for SDH (not shown), in mitochondria prepared from tumours that were injected i.t. with Photofrin II 2 h before killing. Liver mitochondria prepared from the same animals also displayed dose-related inhibitions of both of these enzymes, but at this 2 h time point the extent of inhibition of liver enzymes was considerably less than that observed in tumours (data not shown). The rates of inhibition, calculated as per cent enzyme inhibition per joule per cm2, which were derived from the linear initial portion of the inhibition curves as in Figure 1 , are compiled in Table I . The increases in the enzyme inhibition rates were drug-dose dependent, displaying linearity in tumours for i.t. doses up to 2.5 mg kg-' b.w. and for liver up to 5.0 mg kg-' b.w., results suggesting that a maximum tumour porphyrin level was reached by direct injection. A comparison between tumour and liver mitochondrial preparations, at 2 h after i.t. injection, demonstrated that liver was 5-10-fold less susceptible to photosensitisation for each dose of Photofrin II administered. We interpret these results to indicate that higher concentrations of porphyrin were present in tumour tissue at this time, rather than inherent differences in enzyme sensitivity in these two tissues. Table II . The data clearly demonstrate that photosensitised inhibition of tumour mitochondrial enzymes in vitro 2 h after administration of Photofrin II i.t. was much greater than that observed after i.p. administration (5.45 v. 0.51% and 3.98 v. 0.45% inhibition J-' cm-2 x 10-' for cytochrome c oxidase and succinate dehydrogenase, respectively). At 2 h, the liver mitochondrial enzymes also demonstrated a greater enzyme inhibition rate for i.t. v. i.p. drug admininstration. In tumour preparations obtained at 24 h post-injection, i.t. administration of Photofrin 11 continued to be more effective in causing photosensitised inhibition of both enzymes compared to i.p. injection. However, for the liver preparations, obtained 24 h after drug administration, a difference in response of cytochrome c oxidase and SDH relative to route of administration of photosensitiser was no longer apparent.
Comparison of effects of intratumoral versus intraperitoneal
Photofrin II administration on tumour growth Tumour growth was assessed in both treated and untreated animals by determination of tumour volume at regular intervals after tumours became palpable. Analyses of these data, presented as time in days necessary to attain 2, 5 or 10 times initial volume, are displayed in Figure 2 . Intratumoral Photofrin 1I was administered at a dose of 0.5mgcm-3, which represented a range of 0.81-1.55 mg kg-' b.w. Statistical analysis of the data depicted in Figure 2 , using Tukey's multiple comparison procedure, indicates that Photofrin II at 0.5 mg cm3 tumour i.t. or at 10mg kg-' i.p. caused a statistically significant delay of tumour growth when compared to tumour growth in animals injected i.t. with Photofrin II or 10 mg kg -' i.p. but not irradiated (dark controls). This delay in tumour growth in those animals receiving i.t. Photofrin II Figure 2 . Rates are expressed as per cent enzyme inhibition J-I cm2 x 10' and are presented as means ± s.e.m. Initial activities (0 light) were the same as listed in Table I . 
Discussion
Although combinations of PDT with other treatment modalities, such as X-irradiation (Bellnier & Dougherty, 1986; Winther et al., 1988; Levendag et al., 1989) , chemotherapy using adriamycin (Edell & Cortese, 1988) , cisplatin or doxorubicin (Nahabedian et al., 1988) , hyperthermia by combining PDT with microwave irradiation (Waldow & Dougherty, 1984; Waldow et al., 1987; Levendag et al., 1989 ) and the use of hypoxic cell sensitisers, e.g.
misonidazole (Gonzalez et al., 1986; Winther et al., 1988) (Kostron et al., 1986; Lin et al., 1988a, b) , 1986) , response of the mouse MBT-2 bladder tumour was not enhanced, even though 5-10 times more porphyrin was present in tumours after i.t. injection (Lin et al., 1988 a, b) . Perhaps tumour type and/or host species could account for such apparent differences in response.
In this report, we compared the effects of two routes of drug administration on photosensitisation of mitochondria and on tumour growth after PDT. For study of mitochondrial effects, the in vivo-in vitro protocol was employed, an approach that takes into account any host metabolism and intracellular localisation of the photosensitiser occurring in vivo (Gibson & Hilf, 1983; Gibson et al., 1984b Gibson et al., , 1989 . From such data, we can derive an estimate of the pharmacokinetics of the administered photosensitiser. Previously, after i.p. administration of either HpD or Photofrin II, a time course of photosensitivity of these organelles in vitro indicated that inhibition of mitochondrial function would be greatest when tumours were exposed to light 24-72 h after drug administration (Gibson et al., 1989) . Intratumoral administration of Photofrin II, however, showed a different time-course. At 2 h after i.t. administration, we observed a 10-fold greater rate of photosensitiser-induced inhibition of tumour mitochondrial enzymes than that observed in comparable mitochondrial preparations after animals had received equivalent doses of Photofrin II (5 mg kg-') intraperitoneally. By 24 h after Photofrin II administration, such differences in photosensitivity of enzymes narrow considerably, with only 2-fold greater sensitivity for i.t. than for i.p. routes. These results imply that there were higher concentrations of Photofrin II in tumours shortly after i.t. administration, whereas after i.p. administration, the level of porphyrin at 2 or 24 h, based on mitochondrial enzyme inhibition, was largely unchanged.
A different pattern of photosensitisation of liver mitochondria was observed. Surprisingly, liver mitochondria displayed greater photosensitivity at 2 h after i.t. administration than after i.p. injection, as evidenced by the light-induced inhibition of cytochrome c oxidase and SDH activities. This finding suggests that after direct injection into the tumour, more effective levels of drug reached the liver via the systemic circulation than after i.p. injection. One possbile explanation for this observation might be attributed to the presence of multimeric aggregates versus dimeric and monomeric haematoporphyrin species reaching the liver from the peritoneal injection site. While all of these forms after tissue extraction contribute to the amount of drug measured chemically, not all forms give equal singlet oxygen yields upon photoirradiation (Lambert et al., 1986) . In contrast, at 24 h, liver mitochondrial enzymes were more photosensitive than at 2 h after i.p. injection, suggesting a greater accumulation and/or a slower efflux of active forms of the photosensitiser. A more extensive study of distribution of photosensitiser in other normal tissues after i.t. injection is warranted. The results obtained from examination of mitochondrial enzyme inhibition, using the in vivo-in vitro protocol, were correlatable to effects of PDT on delay of tumour growth.
No significant effects on tumour growth occurred in animals that received Photofrin II (i.p. at 10 mg kg-' or i.t. at 1 mg kg-' b.w.) but were not photoradiated (dark controls), nor in animals that received no drug but light (light controls). In contrast, tumours in animals given Photofrin II i.t. at 1 mg kg-' b.w. and irradiated either at 2 or 24 h later displayed a significant delay in the length of time required to double their initial tumour volume. Most interesting is the finding that subsequent tumour growth, i.e. the time required to increase from 2 times initial size to 10 times initial size, was significantly longer in animals that received i.t. Photofrin II 2 h before light exposure. Mitochondria from tumours of these animals displayed the greatest photosensitivity, implying that the greatest metabolic damage could occur under these conditions. However, vascular damage cannot be excluded as a contributing factor in retarding tumour growth; photosensitivity of liver mitochondria indicates efflux of some i.t. administered drug from the tumour into the systemic circulation. Because prolonged tumour growth retardation was not evident with the other treatment protocols employed, we suggest that vascular damage alone could not be the cause of the observed persistent tumour growth retardation following i.t. injection 2 h before irradiation. Regardless of the mechanism, the data presented demonstrate that intratumoral administration of Photofrin II provides one approach to enhance the effectiveness of PDT on tumour growth.
Although, clinically, lesions may not be accessible or are too numerous to treat by i.t. injections of Photofrin II, there are instances where superficial lesions could be treated by this method of drug delivery. The possibility also exists that, in such cases, the lower amounts of i.t. Photofrin II would result in less skin photosensitivity. Studies directed towards assessing these possibilities are in progress.
